Treats acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or…. ANDA 217887, held by Alembic Therap. Ciprofloxacin Hydrochloride.
As of Nov 21, 2026, ANDA 217887 (Ciprofloxacin Hydrochloride), held by Alembic Therap, was first approved by FDA on Nov 5, 2024, with 0 approved supplements and 0 published complete response letters.
Ciprofloxacin otic solution, 0.2% is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ciprofloxacin HydrochlorideEQ 0.2% BASE · solution/drops;otic | Ciprofloxacin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters